Iranian Knowledge-Based Company Unveils 6 New Medicinal Products
"Slow release buprenorphine 100/300 mg is one of these drugs, which is in the category of painkillers and is used for addiction treatment,” said engineer Ashofteh, the managing-director of the knowledge-based company.
He named variurelix as another drug unveiled by the company for the treatment of infertility, and said it prevents the premature release of LH and consequently the premature maturation of the eggs.
Ashofteh mentioned production of the effective ingredient tetrabenazine as another knowledge-based product of the company, and said, “This product is used in the production of oral medicine tetrabenazine as an effective and active component of the drug.
Tetrabenazine belongs to the category of neurological drugs and is used to reduce uncontrollable movements in Huntington's disease, Hemiballismus, Senile chorea, Tourette's syndrome and Tardive dyskinesia.”
He mentioned nalbuphine hydrochloride as the fourth product of the company, and said, “This product is used in the production of injectable and oral medicine as an effective and active component of the drug.” Ahofteh also described sacubitril/valsartan as another drug unveiled by his company, and noted, “This product is an innovative combination drug used for the treatment of chronic heart failure.”
Earlier reports in August also said that an Iranian knowledge-based company had acquired the formulation of the production of medicines for rare diseases based on biotechnology and has managed to experts them to 15 countries.
“Most of these drugs are prescribed to treat certain patients with rare diseases. The technology used in these drugs is based on biological technologies,” said Mohammad Safariun, the CEO of the pharmaceutical company in an interview with local Iranian media.
He then said that ‘Factor VIII’ is the latest product of the company which is an essential blood clotting protein.
The active substance in Advate, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot. Patients with haemophilia A lack factor VIII, and this causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Safariun pointed to AryoSeven™ as a safe Iranian recombinant activated factor VII as the other product of their company. It is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot. Factor VIIa is to be given only by or under the direct supervision of your doctor.
AryoSeven produced by the company is the first Iranian drug registered in Turkey.
AryoTrust (Trastuzumab) is a biosimilar product produced by the company with the generic name of Trastuzumab. AryoTrust is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
The other medince produced in the company is Stivant which is a recombinant monoclonal antibody.
Also Arylia as the other product of the knowledge-based company is used to treat Osteoporosis in postmenopausal women and in men at increased risk of fractures. Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss in females receiving aromatase inhibitor therapy for breast cancer.
He said a survey they had conducted on the AryoSeven or factor VII showed the complete satisfaction of patients with thwmedicine.
4155/v
